Contents
Contents
Nominal price exception Medicaid fraud involves hiding a reportable drug discount behind a nominal-price label to reduce the rebates owed to Medicaid. A hospital may get the discount while Medicaid pays for prescriptions that follow the patient home. If you work in healthcare contracting or government pricing, you may know both what the discount bought and why it disappeared from best price.
The exception has two parts: how low the price is and who receives it. A deeply discounted sale to a hospital outside the eligible recipient categories fails the recipient test. Calling the price nominal does not make the hospital eligible.
Best price is the lowest qualifying price a manufacturer makes available during the rebate period. It includes cash discounts, volume discounts, rebates and free goods tied to a purchase requirement. A concession can belong in the calculation even when it arrives separately from the invoice.
Leaving out a qualifying low price can raise the reported best price and shrink the Medicaid rebate. Medicaid loses the benefit of a discount that the manufacturer gave another buyer.
Average manufacturer price, often called AMP, measures a different part of the business. Its general definition covers prices paid by wholesalers for drugs distributed to retail community pharmacies and by those pharmacies buying directly.
Manufacturers report quarterly average manufacturer price and best price to the Centers for Medicare & Medicaid Services. States supply the utilization figures used to calculate the rebate payment. Manufacturer-specific price information is confidential, so the contract and calculation inside the company can explain something that a public price list cannot: which sale the manufacturer excluded, and why.
The damage can reach other health care purchasers, too. The 340B ceiling price depends on the Medicaid rebate calculation. An omitted discount that reduces the rebate can also raise the price charged to safety-net providers.
A qualifying nominal sale must meet both a price limit and a recipient requirement. Under the Medicaid rules, the price must be less than 10 percent of average manufacturer price for the same quarter. The comparison is with that quarter’s AMP, not the manufacturer’s list price or the size of the discount advertised to the hospital.
The eligible recipients include 340B covered entities, intermediate care facilities for individuals with intellectual disabilities, state-owned or operated nursing facilities, and public or nonprofit family planning providers. The rules also include certain tax-exempt nonprofits and state entities serving the same populations as a 340B covered entity without receiving the corresponding funding.
The purchaser’s identity matters as much as the price. The contract’s nominal-price designation cannot substitute for eligibility, and an eligible purchaser still needs a qualifying price.
We connect what the customer paid and why it was treated as eligible to the exclusion used in the report.
The Deficit Reduction Act of 2005 changed the recipient side of the exception. Before that change, the statute excluded merely nominal prices without specifying the recipient categories.
That history matters when an old hospital contract becomes the model for a new one. The nominal-price label may survive in a contract template, but the applicable recipient and price rules determine the treatment of the sale.
Merck’s hospital arrangements show the commercial problem behind the exception. The government alleged that the company used prices described as nominal to win business while excluding those discounts from the prices it reported. The cases put the purpose and conditions of the discount at the center of the story.
The Justice Department’s February 2008 Merck announcement described separate settlements involving different drugs and different allegations. A former employee brought the case involving Zocor and Vioxx. A physician brought the Pepcid case.
Merck agreed to pay $399 million to resolve allegations involving Zocor and Vioxx hospital discounts and physician payment programs. The government alleged that hospitals received deep discounts if they used large quantities of those drugs in place of competitors’ brands. Merck allegedly treated the discounted prices as nominal and excluded them from its government price reporting.
Under the government’s account, hospitals received a lower price in exchange for directing more of their drug use toward Merck’s products. That alleged condition explains why the contract matters alongside the invoice: the price came with a commercial objective.
The same settlement also addressed alleged excess payments to physicians disguised as fees for training, consultation or market research to induce use of Merck’s products. The former employee who brought the case received a whistleblower reward of $44.69 million from the federal recovery and $23.5 million from the states.
A nominal hospital drug price can be an investment in outpatient prescription sales, with a rebate consequence for Medicaid. The Pepcid allegations show that connection: Merck allegedly offered substantially reduced prices once hospitals agreed to use Pepcid primarily instead of a competitor’s drug. The government said Merck wanted the spillover business when patients continued buying Pepcid after discharge.
Merck agreed to pay a separate $250 million to resolve that matter. The alleged reporting failure was the omission of the hospital discounts from the prices reported to the government.
The government alleged that Merck used the discount to win hospital business, then used the nominal-price label to keep Medicaid from sharing in it. Under that account, taxpayers lost the rebate benefit of the very discount used to generate more prescriptions.
Wyeth’s Protonix arrangement allegedly pursued the same outpatient business through bundled hospital discounts. Wyeth and Pfizer agreed to a $784.6 million settlement in April 2016 over allegations that Wyeth underpaid Medicaid rebates by excluding those discounts from best price.
According to the government, Wyeth tied discounts on Protonix Oral to discounts on Protonix IV to encourage hospitals to use the oral product. Hospitals otherwise had little incentive to use it because competing oral drugs were priced competitively and considered at least as effective and safe.
The government alleged that patients discharged on Protonix Oral were likely to remain on it for long periods, during which Medicaid and other payers would pay nearly full price. The alleged bargain gave hospitals a discount to win that later business, while keeping the concessions out of the price used to determine Medicaid rebates.
Nominal-price treatment asks whether the price and recipient qualify for exclusion. Bundled-discount treatment asks how a concession conditioned on purchases or performance is allocated across the arrangement. The bundled-sale rule allocates discounts proportionally across the total dollar value of the products sold under the bundle. In an oral and intravenous drug contract, looking at each invoice in isolation can leave that connection out of view.
The two whistleblowers in the Protonix case received a combined reward of about $98 million.
An educational-grant label can also hide a payment that affects best price. In its account of an October 2002 settlement, the Department of Health and Human Services’ Office of Inspector General described allegations that Warner-Lambert paid unrestricted educational grants to a managed care organization to obtain unrestricted formulary status for Lipitor. The government alleged that the company omitted the value of those grants from reported best price. The government’s annual enforcement report records Pfizer’s $49 million settlement.
The alleged benefit was a place for the drug on the health plan’s formulary. Under that account, the educational label concealed what the payment bought: access for Lipitor, with the grant’s value left out of best price.
The Merck, Wyeth and Warner-Lambert allegations point to the same practical question: what did the manufacturer give the purchaser, and where did that value go in the government calculation? A nominal sale, a bundled concession and a grant have different rules, but their labels cannot answer that question by themselves.
The useful evidence connects the purchaser, the commercial bargain and the reported price. The hospital contract shows the products, prices and purchasing conditions. The customer’s eligibility information addresses the recipient test. Quarterly calculations show the AMP comparison and the treatment of the discount.
For a Medicaid rebate calculation, the contract label and the payment have to be read together. A market-share commitment can explain the hospital discount. A grant tied to formulary access can explain money recorded elsewhere. A bundle can explain why the concession on one product belongs in a calculation involving another. We work through those connections with the people who know the accounts.
The assumptions behind the report matter too. The inspector general’s 2019 review found that CMS historically assessed manufacturers’ average manufacturer price and best-price assumptions case by case instead of routinely reviewing them. The manufacturer kept the assumptions inside the business. An employee who knows why a sale was excluded may be able to explain a decision the reported number alone does not reveal.
Price reports must be certified by the chief executive officer, chief financial officer, an equivalent official or someone directly delegated that authority. The connection between the contract, the calculation and the certification helps show who knew what the company was reporting.
A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers. The Merck matters show why both an employee’s knowledge of company practices and a physician’s knowledge of hospital purchasing can matter to a rebate case.
If you know how a hospital discount, purchasing commitment or grant disappeared from Medicaid best price, speak with our whistleblower experts about the contract and the calculation. We work beside you to build the case around the commercial bargain, the reporting decision and the rebates left unpaid. We bring in pharmaceutical fraud whistleblower lawyers who understand government pricing, and we stay with you throughout the case.